Search - tctmd.com

Displaying 1 - 20 of 56

Sort: Relevancy | Date

News Conference News AHA 2025

Beta-blockers Not Helpful After MI in Patients With Preserved EF

Yael L. Maxwell

November 12, 2025

News Conference News AHA 2025

CELEBRATE: Zalunfiban, a Novel Glycoprotein IIb/IIIa Inhibitor, Helps in STEMI

Michael O'Riordan

November 11, 2025

News Conference News AHA 2025

Liberal Transfusion Doesn’t Decrease MACE in Surgery Patients at High Cardiac Risk: TOP

Caitlin E. Cox

November 10, 2025

News Opinion Editor's Corner AHA 2025

What’s Going to Be Hot at AHA 2025?

Michael O'Riordan

November 05, 2025

News Conference News AHA 2024

Talking Sex: CVD Patients Want to Hear More From Clinicians

Caitlin E. Cox

November 20, 2024

News Conference News AHA 2024

Email Nudges Spur Patients With a History of Acute MI to Get Flu Shots

Caitlin E. Cox

November 17, 2024

News Conference News AHA 2024

GLORIOUS: Neither Exenatide Nor Restrictive Oxygenation Boost CV Surgery Outcomes

Michael O'Riordan

November 17, 2024

News Conference News AHA 2024

Spironolactone No Help for the Heart After Acute MI: CLEAR SYNERGY

Shelley Wood

November 17, 2024

Presentation AHA 2024

Routine spironolactone in Acute Myocardial Infarction, results from the CLEAR SYNERGY OASIS 9 trial

Presenter: Sanjit S Jolly

November 17, 2024

News Conference News AHA 2024

One Hundred Years and Beyond: What's Going to Be Hot at AHA 2024

Shelley Wood

November 14, 2024

Presentation AHA 2023

Dapagliflozin in myocardial infarction without diabetes or heart failure

Presenter: Stefan James

November 14, 2023

News Conference News AHA 2023

Automatic Scripts, Pharmacist Phone Calls Boost Statin Prescribing

Shelley Wood

November 14, 2023

News Conference News AHA 2023

MINT Hints at Benefits of Liberal Transfusions in Acute MI With Anemia

L.A. McKeown

November 11, 2023

News Conference News AHA 2023

DAPA-MI: Cardiometabolic Endpoints ‘Win’ With Dapagliflozin After Acute MI

Shelley Wood

November 11, 2023

News Conference News AHA 2023

Coincidental Nonischemic Cardiomyopathy Impacts Prognosis in CAD

Todd Neale

November 09, 2023

News Opinion Editor's Corner AHA 2023

What’s Going to Be Hot at AHA 2023

Shelley Wood

November 07, 2023

News Conference News AHA 2022

Sizeable Minority of Pregnant Women Have CVD, US Data Show

Caitlin E. Cox

November 11, 2022

News Conference News AHA 2022

ISCHEMIA-EXTEND: So Far, Deaths Match for Invasive and Conservative Arms in Stable CAD

Shelley Wood

November 06, 2022

News Conference News AHA 2022

Early ECMO No Better Than Watch-and-Wait Approach in Cardiogenic Shock

Caitlin E. Cox

November 06, 2022

News Conference News AHA 2021

No Benefit for Icosapent Ethyl, P2Y12 Inhibitors in Separate COVID-19 Trials

Todd Neale

November 15, 2021

Advertisement

Beta-blockers Not Helpful After MI in Patients With Preserved EF

CELEBRATE: Zalunfiban, a Novel Glycoprotein IIb/IIIa Inhibitor, Helps in STEMI

Liberal Transfusion Doesn’t Decrease MACE in Surgery Patients at High Cardiac Risk: TOP

What’s Going to Be Hot at AHA 2025?

Talking Sex: CVD Patients Want to Hear More From Clinicians

Email Nudges Spur Patients With a History of Acute MI to Get Flu Shots

GLORIOUS: Neither Exenatide Nor Restrictive Oxygenation Boost CV Surgery Outcomes

Spironolactone No Help for the Heart After Acute MI: CLEAR SYNERGY

Routine spironolactone in Acute Myocardial Infarction, results from the CLEAR SYNERGY OASIS 9 trial

One Hundred Years and Beyond: What's Going to Be Hot at AHA 2024

Dapagliflozin in myocardial infarction without diabetes or heart failure

Automatic Scripts, Pharmacist Phone Calls Boost Statin Prescribing

MINT Hints at Benefits of Liberal Transfusions in Acute MI With Anemia

DAPA-MI: Cardiometabolic Endpoints ‘Win’ With Dapagliflozin After Acute MI

Coincidental Nonischemic Cardiomyopathy Impacts Prognosis in CAD

What’s Going to Be Hot at AHA 2023

Sizeable Minority of Pregnant Women Have CVD, US Data Show

ISCHEMIA-EXTEND: So Far, Deaths Match for Invasive and Conservative Arms in Stable CAD

Early ECMO No Better Than Watch-and-Wait Approach in Cardiogenic Shock

No Benefit for Icosapent Ethyl, P2Y12 Inhibitors in Separate COVID-19 Trials

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content